Why High-Flying Aurinia Pharmaceuticals Stock Could Still Be Dirt Cheap
If 2017 ended today, Aurinia Pharmaceuticals (NASDAQ: AUPH) would rank as one of the biggest winners of the year among biopharmaceutical stocks. Aurinia's share price has more than tripled so far this year.
Is Aurinia overpriced after such tremendous gains? Some might think so. The stock has basically treaded water over the past six months after starting off the year with a roar. However, Aurinia stock is still dirt cheap, in my view, for a couple of key reasons.
Image source: Getty Images.
Source: Fool.com
Bristol-Myers Squibb Stock
€45.30
0.080%
With 7 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 70 € shows a very positive potential of 54.54% compared to the current price of 45.3 € for Bristol-Myers Squibb.
